A Covid-19 vaccine developed by CanSino Biologics and China’s military research unit was shown to be safe and induced immune response in most of the recipients, researchers said.
According to data published in The New England Journal of Medicine, a Phase I trial of Moderna’s mRNA vaccine against SARS-CoV-2 demonstrated promising safety and immune response in all patients involved in the study.
Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine, saying it had been proved safe and that volunteers had developed an immune response.
Moderna Inc.’s experimental vaccine for Covid-19 showed mRNA-1273 was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, U.S. researchers reported.
Developing an ‘Inverse Vaccine’ for Type 1 Diabetes Published: July 14, 2020 By Chelsea Weidman Burke BioSpace What do you get when you mix certain immune cells with vitamin […]
With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.
Novavax entered into a deal with contract drugmaker AGC Biologics to manufacture the company’s experimental COVID-19 vaccine.
Maryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
Ligandal is reportedly the only company developing a prospective “antidote” and vaccine in a single platform for COVID-19, with an approach that could actually help eliminate the virus from an already-infected host, while also bolstering the immune response.
Regeneron and Sanofi dosed the first patient outside of the United States with the rheumatoid arthritis drug Kevzara as part of a second global clinical trial assessing the medication as a treatment for COVID-19, the disease caused by the novel coronavirus pandemic.
